MedTrace Logo

TRIAD - Treatment of Insomnia and Depression

NCT00767624 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2016-12-05

Study results available
· View outcomes & findings →

Summary

The aim of the proposed three-site study is to increase the rate of full remission from major depressive disorder (MDD) at the end of 16 weeks of treatment for people who experience both major depressive disorder and insomnia.

Conditions

  • Sleep Initiation and Maintenance Disorders
  • Depression

Interventions

DRUG

Antidepressant

Possible antidepressants are sertraline, escitalopram, desvenlafaxine, based on past history, response and tolerance

BEHAVIORAL

Desensitization Therapy for Insomnia

BEHAVIORAL

Cognitive Behavioral Therapy for Insomnia

Sponsors & Collaborators

Principal Investigators

  • Rachel Manber · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2015-06-30
Completion
2015-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00767624 on ClinicalTrials.gov